FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
Manag Care
; 28(1): 5-6, 2019 Jan.
Article
em En
| MEDLINE
| ID: mdl-30883313
The FDA commissioner has an 11-step "action plan" to get biosimilars out of a repeat mode of unrealized potential. But issues like interchangeability still need clarifying if biosimilars are to have a major effect on drug expenditures.
Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
United States Food and Drug Administration
/
Custos de Medicamentos
/
Medicamentos Biossimilares
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article